Pub Date : 2000-08-01DOI: 10.1016/S0167-5699(00)01659-5
Annemiek B van Spriel , Heidi H van Ojik , Jan G.J van de Winkel
Bispecific antibodies (BsAb) can, by virtue of combining two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. Recent studies underline the importance of both the ‘anti-trigger’ and ‘anti-target’ modalities of BsAb for therapeutic efficacy. Several BsAb induce effective cytotoxicity as well as ‘vaccine effects’ in vivo. Here, Annemiek van Spriel and colleagues discuss how these results have catalysed renewed efforts to translate BsAb concepts into effective therapies.
双特异性抗体(BsAb)可以通过结合两种结合特异性，提高基于抗体治疗人类疾病的选择性和有效性。最近的研究强调了BsAb的“抗触发”和“抗靶标”模式对治疗效果的重要性。几种BsAb在体内诱导有效的细胞毒性以及“疫苗效应”。在这里，Annemiek van Spriel和他的同事讨论了这些结果如何促进了将BsAb概念转化为有效疗法的新努力。
{"title":"Immunotherapeutic perspective for bispecific antibodies","authors":"Annemiek B van Spriel , Heidi H van Ojik , Jan G.J van de Winkel","doi":"10.1016/S0167-5699(00)01659-5","DOIUrl":"10.1016/S0167-5699(00)01659-5","url":null,"abstract":"<div><p>Bispecific antibodies (BsAb) can, by virtue of combining two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. Recent studies underline the importance of both the ‘anti-trigger’ and ‘anti-target’ modalities of BsAb for therapeutic efficacy. Several BsAb induce effective cytotoxicity as well as ‘vaccine effects’ <em>in vivo</em>. Here, Annemiek van Spriel and colleagues discuss how these results have catalysed renewed efforts to translate BsAb concepts into effective therapies.</p></div>","PeriodicalId":73346,"journal":{"name":"Immunology today","volume":"21 8","pages":"Pages 391-397"},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0167-5699(00)01659-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21756785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-08-01DOI: 10.1016/S0167-5699(00)01682-0
Mike Clark
{"title":"Recombinant antibodies, by Frank Breitling and Stefan Dübel","authors":"Mike Clark","doi":"10.1016/S0167-5699(00)01682-0","DOIUrl":"https://doi.org/10.1016/S0167-5699(00)01682-0","url":null,"abstract":"","PeriodicalId":73346,"journal":{"name":"Immunology today","volume":"21 8","pages":"Page 412"},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0167-5699(00)01682-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91680090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-08-01DOI: 10.1016/S0167-5699(00)01682-0
M. Clark
{"title":"Recombinant antibodies, by Frank Breitling and Stefan Dübel","authors":"M. Clark","doi":"10.1016/S0167-5699(00)01682-0","DOIUrl":"https://doi.org/10.1016/S0167-5699(00)01682-0","url":null,"abstract":"","PeriodicalId":73346,"journal":{"name":"Immunology today","volume":"15 1","pages":"412"},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90337744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-08-01DOI: 10.1016/S0167-5699(00)01683-2
Carl A.K Borrebaeck
Antibodies are used extensively as diagnostic tools in a wide array of different analyses. Monoclonal and recombinant antibodies provide a never ending source of molecules and can produce endless possibilities for novel genetic constructs. Antibodies are still very much in vogue and are now also being used in microarray analysis of the proteome using protein chips. Here, recent opportunities presented by antibodies as diagnostic tools are reviewed.
{"title":"Antibodies in diagnostics – from immunoassays to protein chips","authors":"Carl A.K Borrebaeck","doi":"10.1016/S0167-5699(00)01683-2","DOIUrl":"10.1016/S0167-5699(00)01683-2","url":null,"abstract":"<div><p>Antibodies are used extensively as diagnostic tools in a wide array of different analyses. Monoclonal and recombinant antibodies provide a never ending source of molecules and can produce endless possibilities for novel genetic constructs. Antibodies are still very much in vogue and are now also being used in microarray analysis of the proteome using protein chips. Here, recent opportunities presented by antibodies as diagnostic tools are reviewed.</p></div>","PeriodicalId":73346,"journal":{"name":"Immunology today","volume":"21 8","pages":"Pages 379-382"},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0167-5699(00)01683-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21756783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-08-01DOI: 10.1016/S0167-5699(00)01669-8
Martin J Glennie , Peter W.M Johnson
Much of the 25 years since Kohler and Milstein first described making monoclonal antibodies (mAbs) has been spent trying to develop these reagents to treat human disease. Until recently, progress has been frustratingly slow and by 1994 only one mAb, anti-CD3 (OKT3), had been licensed for clinical use. In the past five years, however, the situation has changed dramatically, with numerous mAbs now showing clinical potential, and a further seven approved for human treatment. Furthermore, all indications are that this upward trend will continue, with a quarter of all new biological products currently undergoing clinical development being antibody based.
{"title":"Clinical trials of antibody therapy","authors":"Martin J Glennie , Peter W.M Johnson","doi":"10.1016/S0167-5699(00)01669-8","DOIUrl":"10.1016/S0167-5699(00)01669-8","url":null,"abstract":"<div><p>Much of the 25 years since Kohler and Milstein first described making monoclonal antibodies (mAbs) has been spent trying to develop these reagents to treat human disease. Until recently, progress has been frustratingly slow and by 1994 only one mAb, anti-CD3 (OKT3), had been licensed for clinical use. In the past five years, however, the situation has changed dramatically, with numerous mAbs now showing clinical potential, and a further seven approved for human treatment. Furthermore, all indications are that this upward trend will continue, with a quarter of all new biological products currently undergoing clinical development being antibody based.</p></div>","PeriodicalId":73346,"journal":{"name":"Immunology today","volume":"21 8","pages":"Pages 403-410"},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0167-5699(00)01669-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21756787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-08-01DOI: 10.1016/S0167-5699(00)01679-0
Jean-Pierre Bouvet , Guillaume Dighiero
{"title":"Cross-reactivity and polyreactivity: the two sides of a coin","authors":"Jean-Pierre Bouvet , Guillaume Dighiero","doi":"10.1016/S0167-5699(00)01679-0","DOIUrl":"10.1016/S0167-5699(00)01679-0","url":null,"abstract":"","PeriodicalId":73346,"journal":{"name":"Immunology today","volume":"21 8","pages":"Pages 411-412"},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0167-5699(00)01679-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21756788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-08-01DOI: 10.1016/S0167-5699(00)01688-1
Phillip R.J. Ansell
The patenting of biological molecules, such as hybridomas and monoclonal antibodies, has become an important issue in biology. While challenging cherished beliefs and practices of many biologists, it has been a central issue for hybridoma and monoclonal antibody research.
{"title":"Hybridoma technology: a view from the patent arena","authors":"Phillip R.J. Ansell","doi":"10.1016/S0167-5699(00)01688-1","DOIUrl":"10.1016/S0167-5699(00)01688-1","url":null,"abstract":"<div><p>The patenting of biological molecules, such as hybridomas and monoclonal antibodies, has become an important issue in biology. While challenging cherished beliefs and practices of many biologists, it has been a central issue for hybridoma and monoclonal antibody research.</p></div>","PeriodicalId":73346,"journal":{"name":"Immunology today","volume":"21 8","pages":"Pages 357-358"},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0167-5699(00)01688-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21756779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-08-01DOI: 10.1016/S0167-5699(00)01660-1
César Milstein
The development of a method to produce monoclonal antibodies against a defined antigen has had profound impact in many branches of research and signalled a shift in the analysis of biological problems. This article describes the background to these developments and their important practical applications that impinge on the relationship between the world of basic science and commerce.
{"title":"With the benefit of hindsight","authors":"César Milstein","doi":"10.1016/S0167-5699(00)01660-1","DOIUrl":"10.1016/S0167-5699(00)01660-1","url":null,"abstract":"<div><p>The development of a method to produce monoclonal antibodies against a defined antigen has had profound impact in many branches of research and signalled a shift in the analysis of biological problems. This article describes the background to these developments and their important practical applications that impinge on the relationship between the world of basic science and commerce.</p></div>","PeriodicalId":73346,"journal":{"name":"Immunology today","volume":"21 8","pages":"Pages 359-364"},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0167-5699(00)01660-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21756780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-08-01DOI: 10.1016/S0167-5699(00)01681-9
Stefan Dübel
The internet has evolved to play a central role in the lives of immunologists. Powerful search engines facilitate the location of references or suppliers at the click of a mouse. Specialized websites provide reviews for many immunological topics and links for fast navigation to related information. This article highlights websites related to monoclonal and recombinant antibodies.
{"title":"The antibody web","authors":"Stefan Dübel","doi":"10.1016/S0167-5699(00)01681-9","DOIUrl":"10.1016/S0167-5699(00)01681-9","url":null,"abstract":"<div><p>The internet has evolved to play a central role in the lives of immunologists. Powerful search engines facilitate the location of references or suppliers at the click of a mouse. Specialized websites provide reviews for many immunological topics and links for fast navigation to related information. This article highlights websites related to monoclonal and recombinant antibodies.</p></div>","PeriodicalId":73346,"journal":{"name":"Immunology today","volume":"21 8","pages":"Pages 355-357"},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0167-5699(00)01681-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21756778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-08-01DOI: 10.1016/S0167-5699(00)01667-4
Hennie R Hoogenboom , Patrick Chames
In the past decade, the drive to develop completely human antibodies for human therapy has led to the development of phage display technology. This technology is able to deliver the ultimate in antibody engineering, that is, high-affinity fully human antibodies to any antigen of choice. Here, this application of phage display technology is reviewed, and the many other antibody-engineering avenues this technology offers are highlighted.
{"title":"Natural and designer binding sites made by phage display technology","authors":"Hennie R Hoogenboom , Patrick Chames","doi":"10.1016/S0167-5699(00)01667-4","DOIUrl":"10.1016/S0167-5699(00)01667-4","url":null,"abstract":"<div><p>In the past decade, the drive to develop completely human antibodies for human therapy has led to the development of phage display technology. This technology is able to deliver the ultimate in antibody engineering, that is, high-affinity fully human antibodies to any antigen of choice. Here, this application of phage display technology is reviewed, and the many other antibody-engineering avenues this technology offers are highlighted.</p></div>","PeriodicalId":73346,"journal":{"name":"Immunology today","volume":"21 8","pages":"Pages 371-378"},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0167-5699(00)01667-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21756782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号